Cartesian Therapeutics, Inc. Reports First Quarter 2026 Financial Results and Corporate Update

Key Highlights from the Q1 2026 10-Q Filing

Quarterly Period Ended: March 31, 2026
Trading Symbol: RNAC, listed on The Nasdaq Stock Market LLC
Common Shares Outstanding as of April 23, 2026: 28,544,728
Registered Security: Contingent Value Rights (CVR) remain outstanding
Registrant Status: Non-accelerated filer, smaller reporting company, not an emerging growth company
Is the Company a Shell Company? No

Total Assets: \$28.4 million as of March 31, 2026 (compared to \$29.4 million as of December 31, 2025)
Net Loss: \$(17.7) million for the three months ended March 31, 2026 (compared to \$(12.5) million for the same period in 2025)
Stockholders’ Deficit: \$(148.1) million as of March 31, 2026 (compared to \$(126.2) million as of December 31, 2025)
Interest Income: \$1.0 million for Q1 2026 (down from \$2.0 million in Q1 2025)
Basic and Diluted Net Loss Per Share: \$(1.46) for Q1 2026 (compared to \$(0.94) for Q1 2025)
Weighted Average Shares Outstanding: 26,855,158 for Q1 2026

Common Stock Issuance: The company issued 2,270,712 shares through at-the-market offerings during Q1 2026, raising net proceeds of \$14.6 million.
Option Exercises: 93,632 shares issued upon exercise of stock options in Q1 2026, bringing in \$0.3 million.
Restricted Stock Awards: 169,278 shares of restricted stock were awarded during the quarter.
Preferred Stock: No preferred stock was outstanding as of March 31, 2026.

The management highlighted several forward-looking factors which may be price sensitive:

The company is operating at a significant and growing net loss, raising concerns about the sufficiency of cash to fund future operations and the need for additional financings.
Stated intentions to monetize legacy assets and potential future payouts under the Contingent Value Rights (CVRs) could provide upside, but there is no guarantee of success or timing.
The company operates in a highly competitive and evolving sector, facing risks from developments in the broader industry, competition, and the need to retain key personnel.
Shareholders are cautioned that forward-looking statements are subject to risks, including but not limited to the sufficiency of capital, regulatory approvals, development timelines, and the impact of future pandemics or similar events.

The company affirms it is current with all reporting obligations under the Securities Exchange Act of 1934.
No defaults upon senior securities were reported during the quarter.
No unregistered sales of equity securities were reported outside of the at-the-market offerings.

Significant Net Loss: The growing net loss and stockholders’ deficit may raise investor concerns regarding future funding and dilution, and could pressure share price.
Active Capital Raising: Recent share issuances via at-the-market offerings demonstrate the company’s reliance on equity markets for funding, with potential dilutive impact.
CVR Payouts: Any announcement regarding monetization of legacy assets or payouts on the CVRs could provide upside and is highly price sensitive.
Ongoing Development Risks: The company’s statements regarding its business strategy, competitive landscape, and risk factors signal that operational progress or setbacks could significantly move the share price.